pemetrexed + cisplatin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Malignant Pleural Mesothelioma

Conditions

Malignant Pleural Mesothelioma

Trial Timeline

Oct 1, 2006 → Feb 1, 2007

NCT ID

NCT00386815

About pemetrexed + cisplatin

pemetrexed + cisplatin is a phase 2 stage product being developed by Eli Lilly for Malignant Pleural Mesothelioma. The current trial status is completed. This product is registered under clinical trial identifier NCT00386815. Target conditions include Malignant Pleural Mesothelioma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00040625	Pre-clinical	Completed	—	—	Mesothelioma
NCT01000480	Phase 2	Completed	Oct 1, 2009	Jul 1, 2013	Non Small Cell Lung Cancer
NCT00887549	Phase 2	Completed	Apr 1, 2009	Jun 1, 2011	Non-Small Cell Lung Cancer
NCT00895648	Phase 2	Terminated	Jan 1, 2009	Oct 1, 2012	Mesothelioma
NCT00475657	Phase 2	Terminated	Oct 1, 2007	Apr 1, 2008	Small Cell Lung Cancer
NCT00447421	Phase 1/2	Terminated	Feb 1, 2007	May 1, 2008	Small Cell Lung Cancer
NCT00415168	Phase 2	Completed	Dec 1, 2006	Jul 1, 2009	Gastric Cancer
NCT00386815	Phase 2	Completed	Oct 1, 2006	Feb 1, 2007	Malignant Pleural Mesothelioma
NCT00374868	Phase 1/2	Completed	Aug 1, 2006	Apr 1, 2008	Urologic Neoplasms
NCT00259285	Phase 2	Terminated	Nov 1, 2005	Dec 1, 2007	Non-Small-Cell Lung Cancer
NCT00251550	Phase 1/2	Completed	Oct 1, 2005	Aug 1, 2006	Malignant Pleural Mesotherioma
NCT00191308	Phase 2	Completed	May 1, 2005	Dec 1, 2010	Non-Small Cell Lung Cancer
NCT00320515	Phase 1/2	Completed	Mar 1, 2004	Jul 1, 2008	Neoplasm, Gastric
NCT00190801	Phase 2	Completed	Sep 1, 2003	Sep 1, 2005	Gastrointestinal Neoplasms
NCT00087698	Phase 2	Completed	Sep 1, 2003	Feb 1, 2008	Pleural Neoplasms

Competing Products

20 competing products in Malignant Pleural Mesothelioma

See all competitors

Product	Company	Stage	Hype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + Bevacizumab	CSPC Pharmaceutical Group Limited	Phase 1/2	40
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	52
Tadalafil + Gemcitabine	Eli Lilly	Phase 1	33
Patritumab Deruxtecan	Daiichi Sankyo	Phase 1/2	41
Tivantinib + FOLFOX	Daiichi Sankyo	Phase 1/2	41
DS-1123	Daiichi Sankyo	Phase 1	33
DS-8201a	Daiichi Sankyo	Phase 1	33
DS-5573a	Daiichi Sankyo	Phase 1	33
DS-6051b	Daiichi Sankyo	Phase 1	33
U3-1565	Daiichi Sankyo	Phase 1	33
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue Medications	Daiichi Sankyo	Phase 1/2	41
DS-3201b + DS-3201b	Daiichi Sankyo	Phase 1	33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kg	Daiichi Sankyo	Phase 1	33
ASP2998 + Pembrolizumab + Enfortumab Vedotin + Carboplatin	Astellas Pharma	Phase 1/2	41
enfortumab vedotin + pembrolizumab	Astellas Pharma	Phase 2	52
CP-461	Astellas Pharma	Phase 2	52
enfortumab vedotin	Astellas Pharma	Phase 1	33
LNF1901 Monoclonal Antibody Injection	Sun Pharmaceutical	Phase 1	33
Perampanel + Standard of Care	Eisai	Phase 1/2	41
Pembrolizumab + Lenvatinib + Placebo for lenvatinib	Eisai	Phase 3	77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved